Residual risk of HIV transmission. High risk for abacavir hypersensitivity reactions (HSR) in patients who test +ve for HLA-B*5701 allele. Do not initiate treatment in patients w/ +ve HLA-B*5701 status, nor in patients w/ -ve HLA-B*5701 status who had suspected abacavir HSR on previous abacavir-containing regimen. Discontinue treatment if HSR is suspected. Increase in wt & blood lipid & glucose levels may occur. Reports of pancreatitis. Reports of virological failure & emergence of resistance at an early stage when combined w/ tenofovir disoproxil fumarate as a once daily regimen. Increased frequency of liver function abnormalities in patients w/ pre-existing liver dysfunction, including chronic active hepatitis. Consider interruption or discontinuation of treatment if there is evidence of worsening liver disease. Increased risk of severe & potentially fatal hepatic adverse reactions in HIV patients co-infected w/ chronic HBV or HCV. Periodic monitoring of both LFTs & markers of HBV replication is recommended if discontinuing treatment in patients co-infected w/ HBV. Reports of mitochondrial dysfunction in HIV -ve infants following exposure
in utero &/or postnatally to nucleoside analogues. Risk of immune reactivation syndrome. Reports of osteonecrosis, particularly in patients w/ advanced HIV disease &/or long-term exposure to CART. Opportunistic infections & other HIV complications may still develop. Observational studies have shown an association between MI & abacavir use. Do not take w/ any other medicinal products containing lamivudine or emtricitabine. Combination of lamivudine w/ cladribine is not recommended. Contains azo colouring agent (sunset yellow). Not recommended in patients w/ CrCl <50 mL/min, & moderate or severe hepatic impairment. Pregnancy. HIV-infected women should not breast-feed to avoid HIV transmission. Elderly >65 yr. Do not administer to childn <25 kg.
Sign Out
